Novolin® L is commonly known as Lente® Human Insulin Zinc Suspension (recombinant DNA origin). The concentration of this product is 100 units of insulin per milliliter. It is a cloudy or milky suspension of 70% crystalline and 30% amorphous human insulin. The insulin substance (the cloudy material) settles at the bottom of the vial, therefore, the vial must be gently agitated or rotated so that the contents are uniformly mixed before a dose is withdrawn. Novolin® L has an intermediate duration of action. The effect of Novolin® L begins approximately 2 1 / 2 hours after injection. The effect is maximal between 7 and 15 hours and ends approximately 22 hours after injection. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. Because of this variation, the periods listed here should be considered as general guidelines only.

This human insulin (recombinant DNA origin) is structurally identical to the insulin produced by the human pancreas. This human insulin is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (bakers' yeast) as the production organism.


Insulin should be stored in a cold place, preferably in a refrigerator, but not in the freezing compartment. Do not let it freeze. Keep the insulin vial in its carton so that it will stay clean and protected from light. If refrigeration is not possible, the bottle of insulin which you are currently using can be kept unrefrigerated as long as it is kept as cool as possible and away from heat and sunlight.

Never use Novolin® L if the precipitate (the white deposit at the bottom of the vial) has become lumpy or granular in appearance or has formed a deposit of solid particles on the wall of the vial. This insulin should not be used if the liquid in the vial remains clear after the vial has been gently agitated.

Never use insulin after the expiration date which is printed on the vial label and carton.


SEE NOVOLIN® 70/30 for complete package insert information on Warning: Insulin Use in Diabetes: Types of Insulins: Syringes: Needle-Free Injectors: Important Statement: Preparing the Injection: Giving the Injection: Usage in Pregnancy: Insulin Reaction and Shock: Diabetic Ketoacidosis and Coma: Adverse Reactions: Important Notes.

Date of Issue: February 1998


Vials, U-100, 100 units/mL, 10 mL, (List No. 183511) (1's)